Douglas L Nguyen1, Lena B Palmer2, Emily T Nguyen3, Stephen A McClave4, Robert G Martindale5, Matthew L Bechtold6. 1. Department of Medicine, University of California Irvine, Irvine, CA, USA. 2. Department of Medicine, Loyola University, Chicago, IL, USA. 3. Department of Pharmacy, University of California - Irvine, CA, USA. 4. Department of Medicine, University of Louisville, Louisville, KY, USA. 5. Department of Surgery, Oregon Health & Science University, Portland, OR, USA. 6. Division of Gastroenterology & Hepatology, University of Missouri Health Sciences Center, CE405, DC 043.00, Five Hospital Drive, Columbia, MO 65212, USA.
Abstract
OBJECTIVES: Many patients with Crohn's disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied. We conducted a meta-analysis to assess the effect of specialized enteral nutrition therapy with infliximab versus infliximab monotherapy in patients with Crohn's disease. METHODS: A comprehensive search of multiple databases was performed. All studies of adult patients with Crohn's disease comparing specialized enteral nutrition therapy (elemental or polymeric diet with low-fat or regular diet) with infliximab versus infliximab monotherapy without dietary restrictions were included. Meta-analysis was performed using the Mantel-Haenszel (fixed effect) model with odds ratio (OR) to assess for clinical remission. RESULTS: Four studies (n = 342) met inclusion criteria. Specialized enteral nutrition therapy with infliximab resulted in 109 of 157 (69.4%) patients reaching clinical remission compared with 84 of 185 (45.4%) with infliximab monotherapy [OR 2.73; 95% confidence interval (CI): 1.73-4.31, p < 0.01]. Similarly, 79 of 106 (74.5%) patients receiving enteral nutrition therapy and infliximab remained in clinical remission after one year compared with 62 of 126 (49.2%) patients receiving infliximab monotherapy (OR 2.93; 95% CI: 1.66-5.17, p < 0.01). No publication bias or heterogeneity was noted for either outcome. CONCLUSIONS: The use of specialized enteral nutrition therapy in combination with infliximab appears to be more effective at inducing and maintaining clinical remission among patients with Crohn's disease than infliximab monotherapy.
OBJECTIVES: Many patients with Crohn's disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied. We conducted a meta-analysis to assess the effect of specialized enteral nutrition therapy with infliximab versus infliximab monotherapy in patients with Crohn's disease. METHODS: A comprehensive search of multiple databases was performed. All studies of adult patients with Crohn's disease comparing specialized enteral nutrition therapy (elemental or polymeric diet with low-fat or regular diet) with infliximab versus infliximab monotherapy without dietary restrictions were included. Meta-analysis was performed using the Mantel-Haenszel (fixed effect) model with odds ratio (OR) to assess for clinical remission. RESULTS: Four studies (n = 342) met inclusion criteria. Specialized enteral nutrition therapy with infliximab resulted in 109 of 157 (69.4%) patients reaching clinical remission compared with 84 of 185 (45.4%) with infliximab monotherapy [OR 2.73; 95% confidence interval (CI): 1.73-4.31, p < 0.01]. Similarly, 79 of 106 (74.5%) patients receiving enteral nutrition therapy and infliximab remained in clinical remission after one year compared with 62 of 126 (49.2%) patients receiving infliximab monotherapy (OR 2.93; 95% CI: 1.66-5.17, p < 0.01). No publication bias or heterogeneity was noted for either outcome. CONCLUSIONS: The use of specialized enteral nutrition therapy in combination with infliximab appears to be more effective at inducing and maintaining clinical remission among patients with Crohn's disease than infliximab monotherapy.
Authors: Susan Armijo-Olivo; Carla R Stiles; Neil A Hagen; Patricia D Biondo; Greta G Cummings Journal: J Eval Clin Pract Date: 2010-08-04 Impact factor: 2.431
Authors: Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts Journal: Gut Date: 2007-01-17 Impact factor: 23.059
Authors: Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts Journal: N Engl J Med Date: 2010-04-15 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Remo Panaccione; A Hillary Steinhart; Brian Bressler; Reena Khanna; John K Marshall; Laura Targownik; Waqqas Afif; Alain Bitton; Mark Borgaonkar; Usha Chauhan; Brendan Halloran; Jennifer Jones; Erin Kennedy; Grigorios I Leontiadis; Edward V Loftus; Jonathan Meddings; Paul Moayyedi; Sanjay Murthy; Sophie Plamondon; Greg Rosenfeld; David Schwartz; Cynthia H Seow; Chadwick Williams; Charles N Bernstein Journal: J Can Assoc Gastroenterol Date: 2018-07-10
Authors: Melinda Moriczi; Gemma Pujol-Muncunill; Rafael Martín-Masot; Santiago Jiménez Treviño; Oscar Segarra Cantón; Carlos Ochoa Sangrador; Luis Peña Quintana; Daniel González Santana; Alejandro Rodríguez Martínez; Antonio Rosell Camps; Honorio Armas; Josefa Barrio; Rafael González de Caldas; Mónica Rodríguez Salas; Elena Balmaseda Serrano; Ester Donat Aliaga; Andrés Bodas Pinedo; Esther Vaquero Sosa; Raquel Vecino López; Alfonso Solar Boga; Ana Moreno Álvarez; César Sánchez Sánchez; Mar Tolín Hernani; Carolina Gutiérrez Junquera; Nazareth Martinón Torres; María Rosaura Leis Trabazo; Francisco Javier Eizaguirre; Mónica García Peris; Enrique Medina Benítez; Beatriz Fernández Caamaño; Ana María Vegas Álvarez; Laura Crespo Valderrábano; Carmen Alonso Vicente; Javier Rubio Santiago; Rafael Galera-Martínez; Ruth García-Romero; Ignacio Ros Arnal; Santiago Fernández Cebrián; Helena Lorenzo Garrido; Javier Francisco Viada Bris; Marta Velasco Rodríguez-Belvis; Juan Manuel Bartolomé Porro; Miriam Blanco Rodríguez; Patricia Barros García; Gonzalo Botija; Francisco José Chicano Marín; Enrique La Orden Izquierdo; Elena Crehuá-Gaudiza; Víctor Manuel Navas-López; Javier Martín-de-Carpi Journal: Nutrients Date: 2020-04-07 Impact factor: 5.717